Medicine and Dentistry
Breast Cancer
100%
Neratinib
40%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
37%
Hormone Therapy
30%
Trastuzumab
27%
Recurrent Disease
25%
Clinical Trial
24%
Adjuvant Therapy
24%
Disease
21%
Salicylate Sodium
18%
Palbociclib
18%
Survival Rate
18%
Neoadjuvant Chemotherapy
18%
Overall Survival
18%
Acetylsalicylic Acid
18%
Minimal Residual Disease
18%
Malignant Neoplasm
18%
Distant Metastasis
18%
Transcriptomics
18%
Cell Interaction
18%
Neoplasm
15%
Pertuzumab
13%
Adjuvant Chemotherapy
12%
Tertiary Care
12%
Estrogen Receptor
12%
Proportional Hazards Model
12%
Disease Free Survival
10%
Metastatic Carcinoma
9%
Targeted Therapy
9%
Progression Free Survival
9%
Monocytic Leukemia
9%
Metastatic Breast Cancer
9%
Blood Group Antibody
9%
One Health
9%
Simple Mastectomy
9%
Placebo
6%
Lenabasum
6%
Radiation Therapy
6%
Side Effect
6%
Health Care Disparity
6%
Surgical Margin
6%
Cancer Staging
6%
Adjuvant
6%
Mammography
6%
Logistic Regression Analysis
6%
Mastectomy
6%
Hormone Receptor
6%
False Positive Result
6%
Keyphrases
Neoadjuvant Chemotherapy
36%
Cure Rate
36%
Neratinib
36%
Breast Cancer Patients
30%
5-year Survival
24%
Breast Cancer
24%
Hospital Effect
18%
Method Comparison
18%
Metastatic Breast Cancer
18%
Disease-free Survival
18%
Access to Care
18%
Ultrasound Image
18%
HER2+ Breast Cancer
18%
Aspirin Use
18%
Safety-net Hospital
18%
Extended Endocrine Therapy
18%
Breast Cancer Index
18%
LILRB4
18%
HER2 Breast Cancer
18%
University Hospital
18%
Texture Analysis
18%
Regret
18%
Residual Disease
18%
Improved Outcomes
18%
CHEK2 mutation
18%
Clinical Teams
18%
Fulvestrant
18%
Distant Metastasis
18%
H-scan Ultrasound
18%
Adjuvant Therapy
18%
Multivariable
12%
Clinical High Risk
12%
Estrogen Receptor-positive
9%
Survival Outcomes
7%
Endocrine Therapy
7%
Pathologic Parameters
6%
Bayesian P-value
6%
Design Discussion
6%
Scaling Methodology
6%
Worse Outcome
6%
Nodal Disease
6%
Aspirin
6%
Placebo
6%
Kaplan-Meier Analysis
6%
Ultra-high Risk
6%
IRB Protocol
6%
Novel Agents
6%
Non-responders
6%
Cox Proportional Hazards Regression Analysis
6%
Selective Estrogen Receptor Modulators
6%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
60%
Neratinib
59%
Fulvestrant
36%
Trastuzumab
36%
Metastatic Breast Cancer
36%
Endocrine Therapy
24%
Estrogen Receptor
21%
Progression Free Survival
20%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
19%
Palbociclib
18%
Taxane
18%
Biological Marker
18%
Non Small Cell Lung Cancer
18%
Epidermal Growth Factor Receptor
18%
Neoplasm
14%
Maximum Tolerated Dose
13%
Monocytic Leukemia
12%
Diarrhea
12%
Recurrent Disease
10%
Protein Tyrosine Kinase Inhibitor
9%
Hormone Receptor
8%
Disease Free Survival
6%
Placebo
6%
Epidermal Growth Factor Receptor Kinase Inhibitor
6%